Janux Therapeutics to Present at Upcoming March Investor Conferences

Rhea-AI Summary

Janux Therapeutics, Inc. (NASDAQ: JANX) announced its participation in three upcoming investor conferences. These include Cowen's 42nd Annual Health Care Conference on March 7, Barclays Global Healthcare Conference on March 16, and Oppenheimer's 32nd Annual Healthcare Conference on March 17. Janux focuses on developing innovative immunotherapies using its proprietary TRACTr and TRACIr platforms. The company aims to address challenges in treating solid tumors with its lead product candidates targeting PSMA, EGFR, and TROP2, currently in various stages of development.

SAN DIEGO--(BUSINESS WIRE)-- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate in three upcoming investor conferences:

Cowen’s 42nd Annual Health Care Conference
Forum: Panel titled “Novel IO”
Location: Virtual
Date: Monday, March 7
Time: 10:30 a.m. – 11:30 a.m. ET

Barclays Global Healthcare Conference
Forum: Corporate Presentation
Location: Miami, Florida
Date: Wednesday, March 16
Time: 2:35 p.m. – 3:00 p.m. ET

Oppenheimer’s 32nd Annual Healthcare Conference
Forum: Corporate PresentationLocation: Virtual
Date: Thursday, March 17
Time: 8:40 a.m. – 9:10 a.m. ET

All presentations and subsequent archived replays may be accessed via the Investors & Media section of Janux’s website. An archived replay of the webcasts will be available on the website for approximately 90 days following the presentation.

About Janux Therapeutics
Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors have faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations. Janux is developing a broad pipeline with lead TRACTr programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2), and its lead TRACIr program targeting PD-L1xCD28, with all of its programs currently in the IND-enabling or discovery stage. For more information, please visit www.januxrx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220301005026/en/

Media:

Jessica Yingling, Ph.D.

Little Dog Communications Inc.

jessica@litldog.com

(858) 344-8091

Investors:

Christina Tartaglia

Stern Investor Relations, Inc.

christina@sternir.com

(212) 362-1200

Source: Janux Therapeutics, Inc.

FAQ

What conferences will Janux Therapeutics participate in March 2023?

Janux Therapeutics will participate in Cowen's 42nd Annual Health Care Conference on March 7, Barclays Global Healthcare Conference on March 16, and Oppenheimer's 32nd Annual Healthcare Conference on March 17, 2023.

What is the focus of Janux Therapeutics' development?

Janux Therapeutics focuses on developing novel immunotherapies using its TRACTr and TRACIr platforms to treat cancer, specifically targeting solid tumors.

What are the lead product candidates of Janux Therapeutics?

Janux's lead product candidates target prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2).

How can investors access Janux's conference presentations?

Investors can access Janux's conference presentations and archived replays via the Investors & Media section on Janux's website.

What technology platforms does Janux Therapeutics utilize?

Janux Therapeutics utilizes proprietary technology platforms called Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) in its development efforts.